Editor’s Note: October 26, 2012
Dear Readers, What an exciting week in our sector. Our Sentinel this week focuses on a handful of companies with powerful technology. Our “above the […]
Month: September 2012
Bulls, Bears: Sepsis and Anti-Infectives in the Public Markets
The threat of infection in hospital and other treatment facilities have dramatically increased over the last few years. Antibiotics and other therapies have become impotent against certain pathogens and infections, increasing the need for research funding for creating new antibiotics. These three companies have the potential to solve a significant unmet medical need.
Smart Stocks Watch: Ampio Pharmaceuticals — Sexual Dysfunction, Ophthalmology, Nephrology
Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a clinical-stage biopharmaceutical company developing drugs for sexual dysfunction, inflammatory diseases and ophthalmological conditions has announced a manufacturing agreement with drug delivery maker Enthypharm Ltd for Zertane, Ampio’s drug for the treatment of premature ejaculation (PE).
OneMedRadio: AdvaMed 2012 — What to Watch For
OneMedRadio spoke with Ray Briscuso, Managing Partner and Producer of AdvaMed 2012, to learn about the can’t miss highlights in conference programming. Briscuso also discussed the history of the conference — how a gathering once geared toward trade association types has grown into one of the most important events in facilitating growth company finance in the sector.
AdvaMed 2012: The MedTech Sector Event of the Year
The 6th Annual AdvaMed 2012 MedTech Conference kicks off October 1st for a 3-day event covering the hottest issues in the sector. This year, AdvaMed expects more than 2,100 attendees, 800 MedTech companies from 24 countries, 36 states and DC.
Forward Stock Split — Sept 24, Medivation, Inc
Medivation, Inc [Nasdaq: MDVN] today announced that it has effected a 2-for-1 forward split of all shares of its common stock and increased the authorized […]
PDUFA: Sept 30 — NPS Pharmaceuticals
NPS Pharmaceuticals expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) on the approval status of GATTEX, being developed for the treatment of adult short bowel syndrome.
PDUFA: Oct 16 — Santarus, Inc **Extended to January 16, 2013**
Santarus, Inc. expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) on the approval status of UCERIS, being developed for the treatment […]
PDUFA: Oct 19 — Supernus Pharmaceuticals
Supernus Pharmaceuticals [Nasdaq: SUPN] expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) on the approval status of SPN-804, being developed for […]
Smart Stocks Watch: Apricus Bio — Erectile Dysfunction, Anti-Fungals
The San Diego-based pharmaceutical company has five approved products internationally, covering erectile dysfunction (Vitaros), side effects of cancer therapy (Totect and Granisol), coronary artery disease (Nitromist) and dry mouth (Aquoral). After a series of successes in strategic partnerships, acquisitions, peer review and clinical data in Q3, the company is garnering some serious attention.